(EMAILWIRE.COM, December 13, 2018 ) The increasing number of donations, its low cost, growing prevalence/incidence of infectious diseases, and the increasing demand for donated blood are the major factors contributing to the growth of the ELISA market. Moreover, the high cost of NAT testing makes it unaffordable for developing economies, leaving them to rely on ELISA testing for blood screening.

Get Discount on Report @ https://www.marketsandmarkets.com/discountreports.asp?id=267747042

Blood Screening Market is broadly classified into technology, product & service, end user, and region. The ELISA segment is projected to register the highest CAGR during the forecast period.

The global blood screening market is expected to reach USD 2.80 billion by 2021 from USD 1.76 billion in 2016, at a CAGR of 9.7%

Major Market Development:

-In June 2016, Grifols and Hologic, Inc. (U.S.) announced the U.S. FDA approval of the Procleix Zika virus blood-screening assay on the Procleix Panther system under the agency's Investigational New Drug (IND) study protocol. This enhanced the company’s portfolio of blood screening products.

-In October 2016, Roche announced the FDA approval of the cobas MPX test for use on the cobas 6800 and 8800 Systems. This detects HIV-1, HIV-2, HBV, and HCV in transfused blood products.

-In July 2015, Roche announced the market availability of the Elecsys HTLV-I/II immunoassay. This diagnostic test detects antibodies against Human T-lymphotropic virus I & II infections in donated blood and routine diagnostic samples.

Download FRER Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042

Target Audience for this Report:
-Blood Screening Instruments and Reagents Manufacturers
-Blood Screening Software and Services Providers
-Blood Banks
-Hospitals
-Red Cross Societies
-Regulatory Bodies
-Research and Consulting Firms
-Government Bodies

The major players in the blood screening market are Grifols (Spain), Bio-Rad Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Abbott Laboratories (U.S.), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Ortho Clinical Diagnostics, Inc. (U.S.), and Becton, Dickinson and Company (U.S).

This end user segment includes blood banks operated by governments, charitable trusts, and those connected to hospitals. In most developed countries, blood banks are operated by nongovernment organizations (NGOs). The American Red Cross Society monitors blood transfusion services in the U.S. Blood transfusion services are an integral part of the National Health Service (U.K.), as there are no substitutes for blood and blood components. This growth is attributed to the increasing demand of blood for the treatment of clinical conditions like sickle-cell anemia, thalassemia, cancer, hemophilia or thrombocytopenia, liver failure, and severe burns.

Request for Bundle Reports @ https://www.marketsandmarkets.com/RequestBundleReport.asp?id=267747042